Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Targeting Cytochrome P450 Enzymes in Ovarian Cancers: new approaches for Tumour-Selective Interventions

Yousef M. Al-saraireh
* ORCID logo ,
Fatemah O. F. O. Alshammari
ORCID logo ,
Omar H. Abu-azzam
,
Sa’ed M. Al-dalain
,
Yahya M. Al-sarayra
,
Mansour Haddad
ORCID logo ,
Hafiz Makeen
ORCID logo ,
Aiman Al-Qtaitat
,
Mohammad Almermesh
,
Sameeh A. Al-sarayreh
Version 1 : Received: 31 August 2023 / Approved: 4 September 2023 / Online: 4 September 2023 (11:58:30 CEST)

A peer-reviewed article of this Preprint also exists.

Al-saraireh, Y.M.; Alshammari, F.O.F.O.; Abu-azzam, O.H.; Al-dalain, S.M.; Al-sarayra, Y.M.; Haddad, M.; Makeen, H.; Al-Qtaitat, A.; Almermesh, M.; Al-sarayreh, S.A. Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention. Biomedicines 2023, 11, 2898. Al-saraireh, Y.M.; Alshammari, F.O.F.O.; Abu-azzam, O.H.; Al-dalain, S.M.; Al-sarayra, Y.M.; Haddad, M.; Makeen, H.; Al-Qtaitat, A.; Almermesh, M.; Al-sarayreh, S.A. Targeting Cytochrome P450 Enzymes in Ovarian Cancers: New Approaches to Tumor-Selective Intervention. Biomedicines 2023, 11, 2898.

Abstract

Over the past decade, significant developments have occurred in treatment strategies for ovarian cancer, yet targeted therapy with few side effects is still a major issue. The cytochrome P450 (CYP) enzyme family plays a vital role in the tumorigenesis process and metabolism of drugs, with a negative impact on therapy outcomes. Gaining more insight into CYP expression is crucial for understanding the pathophysiology of ovarian cancer since many isoforms are essential for the metabolism of xenobiotics and steroid hormones, which drive the disease's development. The purpose of this review is to provide a clear understanding of differential CYP expression in ovarian cancer and its implications for the prognosis of ovarian cancer patients, together with their polymorphisms' effect on chemotherapy metabolism. Finally, we provide our thoughts on opportunities to exploit metabolic CYP expression for novel therapeutic development to treat ovarian cancer.

Keywords

cytochromes P450; ovarian cancer; gynecologic cancers; pro-drug; xenobiotics; prognosis

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.